In part two of a two-part interview, WInnovations host Dr. Kyle Richards is joined by Dr. Elizabeth Koehne, assistant professor and urologic oncologist at the University of Wisconsin Department of Urology, and Dr. Sam Chang, professor and chief of urologic oncology at Vanderbilt University. The conversation continues with a deeper dive into emerging treatments for non–muscle invasive bladder cancer, with a particular focus on the growing role of biomarkers in guiding care and identifying the right therapy for the right patient. The discussion also further explores evolving strategies for patients with BCG-unresponsive disease, including promising therapeutic options amid the ongoing BCG shortage.